expander or implant removal and systemic antibiotic therapy for up to 2 weeks for common infections. 19 Reimplantation following removal can be attempted within 3 to 6 months, although this may not be possible in cases involving chest wall radiotherapy. 20 To attempt salvage of prosthetic reconstruction, systemic antibiotics without implant removal may be successful in a subset of patients with mild surgical-site infections. 21, 22 Such management frequently requires long-term antibiotic treatment and can lead to delay or disruption of oncologic therapy. Previous studies have reviewed single-surgeon or institutional outcomes following tissue expander or direct-toimplant reconstructions in attempts to ascertain infection and reconstructive failure rates and identify associated risk factors. [7] [8] [9] Recently, larger population studies have been performed on a broader scale using national databases such as the National Surgical Quality Improvement Program and Tracking Operations and Outcomes for Plastic Surgeons registry. 1, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] These studies have offered important insights into surgical complication rates and suggested comorbidities that portend failure of implant-based breast reconstruction on a population level. However, these databases only capture up to 30-day outcomes following a procedure and do not allow for any long-term clinical outcome assessment. Thus, many recently published surgical-site infection complication rates in implant-based breast reconstruction are limited solely to early infections.
Although it has generally been assumed that the vast majority of surgical-site infection complications occur within 30 days after a procedure, late infections are frequently observed several months or even years after implant-based breast reconstruction. 25 The consequences of late surgical-site infection are just as serious as early surgical-site infection, and the treatment is not any easier. Despite this fact, the rate of late surgical-site infection is unknown, and the associated risk factors for late surgical-site infection are unclear. The goal of the present study was to evaluate the rates of both early (≤30 days) and late (>30 days to 1 year) surgical-site infections in immediate implant-based breast reconstruction and to identify predictors using a post hoc analysis of data from a large prospective multicenter trial.
PATIENTS AND METHODS
Patients were recruited as part of the Mastectomy Reconstruction Outcomes Consortium Study, a 5-year, prospective, multicenter cohort study of mastectomy reconstruction patients funded by the National Cancer Institute. Women aged 18 years or older undergoing first-time unilateral or bilateral mastectomy breast reconstruction were eligible for participation. Fifty-seven plastic surgeons from 11 centers in the United States (i.e., Michigan, New York, Illinois, Ohio, Massachusetts, Washington, D.C., Georgia, and Texas) and Canada (i.e., British Columbia and Manitoba) contributed patients to the study, which began in February of 2012. Appropriate institutional review board approval was obtained from all participating sites. From the study, 1662 implant-based breast reconstructions in 1024 patients were evaluated for early versus late surgical-site infection.
Early surgical-site infection was defined as infection occurring within 30 days after surgery, and late surgical-site infection was defined as infection occurring between 31 days and 1 year after surgery. Direct-to-implant patients had a minimum 1-year follow-up, and tissue expander patients had a 2-year follow-up, including minimum 1-year follow-up data from the second-stage exchange procedure. Minor infection was defined as surgical-site infection successfully treated with outpatient oral antibiotics, and major infection was defined as surgical-site infection requiring inpatient hospitalization and/or operative treatment.
Clinical and demographic characteristics of the cohort were summarized by those with no surgical-site infection, those with early surgicalsite infection, and those with late surgical-site infection. Occurrence of surgical-site infection was expressed as percentages by timing (early versus late) and type (major versus minor) and was also summarized by direct-to-implant and tissue expander procedures. All analyses were performed with breast as the analytical unit, except for the demographic characteristics, which were summarized at the patient level. A mixed-effects logistic regression model was used at the breast level to further identify potential predictors for late surgical-site infection. The model included body mass index, reconstructive procedure type (direct-to-implant versus tissue expander), indication for mastectomy (prophylactic versus cancer), acellular dermal matrix use, smoking status, and radiation therapy as independent variables. The model also included random intercepts for hospitals and for patients nested within hospitals to account for between-center and between-patient variability. We reported adjusted odds ratios, 95 percent confidence intervals, and corresponding Plastic and Reconstructive Surgery • January 2017 p values based on the model. All statistical analyses were performed in SAS 9.4 (SAS Institute, Inc., Cary, N.C.), and statistical significance was set at 0.05.
RESULTS

Demographic Data
A total of 1662 breast reconstructions in 1024 patients were included in the study. Among these, 1491 reconstructions were two-stage procedures performed with immediate tissue expander placement and 171 reconstructions were performed as single-stage procedures using a direct-to-implant approach. Demographic data ( Table 1 ) demonstrated a mean age of 48 ± 10.6 years. Mean body mass index was 25.8 ± 5.6 kg/m 2 , 2.1 percent of patients were smokers at the time of reconstruction, and 3.5 percent had diabetes; 90.4 percent of patients had zero or one comorbid medical condition.
The overall surgical-site infection rate was 9.9 percent (17 of 171) in the direct-to-implant group and 7.7 percent (114 of 1491) in the tissue expander group. Of note, 47.1 percent of surgical-site infections in the direct-to-implant group and 56.0 percent of surgical-site infections in the tissue expander group were late surgicalsite infections occurring 30 or more days after the initial reconstruction (eight of 17 direct-toimplant patients and 65 of 116 tissue expander patients) ( Table 2 ). The major infection rate was 6.4 percent (11 of 171) in the direct-to-implant group, with 45 percent (five of 11) occurring as late surgical-site infection; and the major infection rate was 3.4 percent (51 of 1491) in the firststage tissue expander group, with 51 percent (26 of 51) occurring as late surgical-site infection. The minor infection rate was 3.5 percent (six of 171) in the direct-to-implant group, with 50 percent (three of six) occurring as late surgical-site infection; and the minor infection rate was 2.3 percent (35 of 1491) in the first-stage tissue expander group, with 49 percent (17 of 35) occurring as late surgical-site infection (Fig. 1) . There was no significant difference between direct-to-implant and tissue expander groups in the rates of early, late, or overall surgical-site infection.
A total of 1266 tissue expander reconstruction patients underwent second-stage exchange for implants. Of note, the second-stage procedures were found to be significantly more prone to late surgical-site infection than early surgical-site infection. The overall surgical-site infection rate for second-stage procedures was 2.5 percent (31 of 1266), with 71 percent (22 of 31) occurring as late surgical-site infection 30 or more days after the exchange procedure ( Fig. 1) .
A significant percentage of late surgical-site infection cases resulted in explantation of the prosthesis (Table 3) Plastic and Reconstructive Surgery • January 2017
Multivariate analysis identified two predictors of late surgical-site infection following implantbased breast reconstruction. These predictors included radiation therapy following first-stage tissue expander placement (OR, 2.93; p = 0.001) and increased body mass index (OR, 1.08; p = 0.000) as significant predictors of late surgical-site infection (Table 4) . Use of acellular dermal matrix, prereconstruction radiotherapy, radiotherapy following implant placement, and therapeutic versus prophylactic mastectomy were not associated with late surgical-site infection. Figure 2 illustrates a clinical case example of late surgical-site infection that occurred 10 months after a second-stage tissue expander-toimplant exchange procedure. The patient had cancer affecting the left breast and underwent bilateral mastectomy and immediate breast reconstruction using tissue expander and acellular dermal matrix followed by left chest wall radiotherapy. Although good cosmetic outcome was maintained through radiotherapy and for months after the second-stage exchange procedure, late surgical-site infection developed 10 months after the second-stage procedure, leading ultimately to significant capsular contracture and compromise of reconstructive outcome.
DISCUSSION
Reported infection rates following prosthetic breast reconstruction for mastectomy defects range from 1 to 35 percent. 26, 27 Surgical-site infection is highly predictive of subsequent implant failure. 7 Prophylactic and perioperative antibiotics are known to decrease surgical-site infection rates, whereas postoperative hematomas and seromas increase the overall rate. 28 Most early surgical-site infections and implant failures are associated with endogenous skin flora that colonize the nipple, including Staphylococcus aureus, streptococci and lactobacilli species, and Propionibacterium acnes. 29, 30 Although most surgical-site infections are generally thought to occur within months, some are observed to occur even after many years. 26 The Centers for Disease Control and Prevention defines deep incisional surgical-site infection to be infection occurring within 1 year after the operation when an implant is in place. 31 However, up to this point, the true rate of late infections in implantbased breast reconstruction has been unknown.
The present study demonstrates that the majority of surgical-site infection complications in immediate implant-based breast reconstructions are late infections occurring later than 30 days postoperatively following either first-stage or second-stage procedures. Our data show that 47 to 71 percent of total surgical-site infection complications occur as late infections. This finding is of particular concern because of the recent popularity of large database studies using national registries such as the National Surgical Quality Improvement Program and the Tracking Operations and Outcomes for Plastic Surgeons registry. 32 Although such studies generate study populations of impressive size and appear to allow more robust analysis of complications and outcomes, their data collection is limited to a 30-day period after surgery and therefore is limited to short-term complications and outcomes. A small descriptive study by Luce and Pierce evaluating a cohort of tissue expander breast reconstructions suggested that greater numbers of tissue expander explantations occur beyond the 30-day postoperative window and questioned the appropriateness of using the National Surgical Quality Improvement Program database to examine these patients. 33 Similarly, Cohen et al. determined that the median time to explanation following implant-based breast procedures is 41 days and commented that only 50 percent of surgical-site infections occurred within the 1-month time-point. 34 Our current study confirms that a majority of surgical-site infection cases in this patient population occur later than 30 days after surgery and suggests that recent national database studies significantly underestimate the risk of actual surgical-site infection in implantbased breast reconstructions.
Although the etiologic mechanisms of late infection remain unclear, early colonization may result in the formation of a biofilm and subsequent subacute infection that only manifests in delayed fashion after many months. 35 Late surgical-site infection may also be associated with capsular contracture. [36] [37] [38] Recent studies suggest that late-onset capsular contracture may simply be a manifestation of chronic infection and biofilm formation. 39 In patients with implants removed Fig. 2 . A 39-year-old woman who was diagnosed with left breast cancer. The patient is seen following bilateral mastectomy with acellular dermal matrix and tissue expander reconstruction, followed by postmastectomy radiation therapy of the left chest during expansion. The patient is seen 2 months after tissue expander exchange for implant (above). At 10 months after a tissue expander-to-implant exchange procedure, mild cellulitis can be visualized overlying the left chest (center). After intravenous antibiotic treatment and resolution of cellulitis, the patient now has capsular contracture and obvious asymmetry (below).
for capsular contractures, 33 to 41 percent were associated with colonization by skin flora. 39, 40 The relationship between biofilm and capsular contracture remains unclear and warrants further research. 41 In the present study, radiation therapy was identified as one of the significant independent risk factors for late surgical-site infection, particularly following second-stage tissue expander exchange procedure. This finding is consistent with prior studies reporting chest wall irradiation as a significant risk factor for overall breast surgical-site infection. [42] [43] [44] In a recent study, radiation therapy increased the rate of permanent implant infection and removal by approximately 5-fold compared with nonirradiated breasts, similar to the odds ratio of 4 that our study observed. 45 In a separate study with a longer follow-up period, 9 percent of postmastectomy irradiation patients suffered implant loss, compared with 0.5 percent in the control population. 46 Radiation therapy also reduces the likelihood of implant salvage following infection or prosthesis exposure. 47 Many of these studies are limited by short-term follow-up, and outcomes specifically following the second-stage procedure are lacking. To the authors' knowledge, the current study reports surgical-site infection outcomes from the largest population of second-stage exchange procedures (n = 1266) with a minimum 1-year follow-up to date. Moreover, strict use of Centers for Disease Control and Prevention definitions of surgical-site infection in the data set results in the most complete and accurate assessment of surgical-site infection rate to date.
Although two-stage breast reconstruction using a tissue expander exchange-to-implant procedure is generally considered to be a simple and benign operations with a minimal complication risk, our study results show that the rate of late infection may have been vastly underappreciated in this patient population, with up to 71 percent of surgical-site infections occurring as late infections. Moreover, postmastectomy radiotherapy may produce tissue changes, including progressive soft-tissue fibrosis and vascular compromise that is likely to contribute to the overall increased risk of late-onset surgical-site infection complications, even following second-stage exchange procedures.
Our study also identified higher body mass index as a significant predictor for late surgicalsite infection. This is not a novel concept in the surgical literature, and many previous studies have reported obesity as a significant risk factor for surgical-site infection in general. 48, 49 Obesity is frequently associated with macromastia. Large preoperative breast volume results in significant dead space following mastectomy, and placement of a substantial foreign body burden (implant or tissue expander) in the setting of already tenuous soft-tissue envelope coverage can lead to infection. Postoperative seroma is also commonly encountered with obesity, and this can be especially challenging to detect in obese patients. Residual seroma after initial surgical drain removal may be a trigger for late-onset infections. Although most reconstructive surgeons certainly understand obesity as a well-established risk factor for not only surgical complications but also poor aesthetic outcome in implant-based breast reconstruction, this patient group unfortunately has an increased risk of surgical complications even with autologous breast reconstruction. 50 The present study identified that the risk for late surgical-site infection increased by 8 percent per each point increase in body mass index. It may therefore be wise to counsel obese patients regarding the late-onset infection complications and reconstruction failure risks and to consider a delayed breast reconstruction approach.
Although the present study provides valuable data from a large, prospective, multicenter cohort from the Mastectomy Reconstruction Outcomes Consortium study, it does have a number of limitations. Although the early, late, and overall surgical-site infection rates are well documented, our analysis is limited by the absence of additional data points, such as culture results, duration of antibiotic treatment, drain use, and duration of neoadjuvant or adjuvant therapy. In addition, given the nature of a multicenter cohort design, there may be variations in the surgical-site infection evaluation and treatment protocol among the participating institutions, including the criteria for inpatient hospitalization and intravenous antibiotics, explantation versus salvage, and radiotherapy protocol. Nonetheless, the results illustrate the remarkable underestimation of the rate of surgical-site infections in implant-based breast reconstruction and identify important predictors for late infections that can play a significant role in patient counseling. Finally, the number of patients undergoing direct-to-implant reconstruction was relatively small, which limits the power of our study to make conclusions regarding this patient group. Future research directions should incorporate an even longer follow-up period, with evaluation of associations between incidences of surgical-site infections and postoperative period.
CONCLUSIONS
The majority of surgical-site infection complications following immediate implant-based breast reconstructions are late infections that present more than 30 days after surgery following either the first or second stage of surgical treatment. Radiotherapy and higher body mass index are significantly associated with late-onset surgical-site infection. The National Surgical Quality Improvement Program database captures data limited to 30 days after surgery and may underreport surgical-site infection complications in this patient population. Recent studies using the National Surgical Quality Improvement Program and other large national registries therefore may not present an accurate or complete assessment of infection complications associated with implant-based breast reconstructions or their long-term clinical outcomes. Preoperative counseling when considering implant-based breast reconstruction should incorporate discussions regarding the risk of late surgical-site infections and its specific risk factors-radiotherapy and obesity. 
